Epidemiology of Chikungunya in the Americas

Sergio Yactayo,1 J. Erin Staples,2 Véronique Millot,1 Laurence Cibrelus,1 and Pilar Ramon-Pardo3

1Department of Pandemic and Epidemic Diseases, World Health Organization, Geneva, Switzerland; 2Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado; and 3Department of International Health Regulations, Pan American Health Organization/World Health Organization, Washington D.C.

Chikungunya virus (CHIKV) emerged in the Americas in late 2013 to cause substantial acute and chronic morbidity. About 1.1 million cases of chikungunya were reported within a year, including severe cases and deaths. The burden of chikungunya is unclear owing to inadequate disease surveillance and underdiagnosis. Virus evolution, globalization, and climate change may further CHIKV spread. No approved vaccine or antiviral therapeutics exist. Early detection and appropriate management could reduce the burden of severe atypical and chronic arthritic disease. Improved surveillance and risk assessment are needed to mitigate the impact of chikungunya.

Keywords. chikungunya; epidemiology; arbovirus; emerging disease; Americas.

Chikungunya virus (CHIKV) is an arthropod-borne alphavirus primarily transmitted by Aedes mosquitoes, which are endemic in tropical areas of Africa and Asia. It is also capable of causing explosive outbreaks of human disease in areas with no prior immunity, such as those in Europe and the Americas. Studies of prior outbreaks have determined that 10%–70% of persons in an affected area become infected [1, 2]. This potentially high infection rate is coupled with a high symptomatic attack rate among infected people, with 50%–97% developing clinical disease with fever and polyarthralgia [2–4], and yields large outbreaks of disease that often tax existing healthcare systems and public health infrastructure.

Serosurveys conducted during postepidemic phases detected immunoglobulin M/immunoglobulin G in 38.2% of surveyed populations in the Indian Ocean island of La Reunion [1], 75% in the Kenyan island of Lamu, 63% in Grande Comoro Island [2], and 90.4% in Suriname [5]. These findings suggest that the CHIKV was broadly transmitted during the outbreak.

A total of 3%–22% of infected patients are asymptomatic or pauci-symptomatic [2, 4].

The recent expansion of CHIKV in the Americas highlights several of the features of this reemerging virus. It spreads rapidly, affecting populated areas with no prior immunity. Areas with outbreaks of other arboviruses, such as dengue virus and yellow fever virus, are at substantial risk of large CHIKV outbreaks since these viruses share similar ecology and vector transmission cycles with CHIKV. Although chikungunya is often described as a self-limited illness, rare but serious disease and death associated with CHIKV have been observed. In La Reunion, 51% of infected children had a global neurodevelopmental delay, compared with 15% of uninfected children [6]. Nevertheless the neurotropism of chikungunya has not been completely defined, and animal studies show some inconsistencies in the capacity for CHIKV to invade the brain parenchyma [7]. In addition, outbreaks from other regions, such as La Reunion, highlighted that CHIKV is capable of undergoing mutation that increases its infectivity for Aedes albopictus, which allows the virus to spread into areas where there is minimal population immunity. Nevertheless, there is no evidence that human clinical presentation in the Americas differs from that in La Reunion [8].

CHIKUNGYNA IN THE PAST

Before December 2013, local CHIKV transmission had not been identified in the Americas. The potential first reports of a chikungunya-like illness were recorded in 1823, in Zanzibar, where it was called kidinga pepo, a Swahili term meaning a disease characterized by a sudden cramp-like seizure. However, it was only years later that an epidemic of this disease was described in Zanzibar by Christie, in an 1872 issue of the British Medical Journal [9]. In 1827 and 1828, a chikungunya-like disease was described in St. Thomas Island in the Caribbean and later affected New Orleans, Louisiana, and part of South Carolina in the United States [9].

In 1928, Dumaresq, who observed a “denga” epidemic in New Orleans, explained how the chikungunya-like disease was imported into Havana, Cuba, by slaves coming from Africa. As recently recalled by Halstead, Dumaresq provided a precise clinical description of the disease as “[a] person on the...
disappearance of this fever would attempt to rise from bed, feeling not much loss of strength, and a consciousness of being able to move about and attend to a little to business; but how egregiously would he be mistaken when he assumed the upright posture! The joints felt as if fettered or anchylosed, and the advance of one foot or leg beyond the other, would cost more pain and effort than the purpose for which it may have been advanced was worth, — ay, — a thousand times told!” [9, 10].

The word chikungunya appeared for the first time in Tanzania in the 20th century, where in Makoña language it means “to walk bent over” and refers to the stooped posture of patients experiencing the joint pains that characterize this dengue-like infection [9]. Following the first identification of CHIKV in Tanzania, in 1952, the virus was then identified to cause sporadic cases of disease and localized outbreaks in Africa and parts of Asia. In 2004, the virus seemed to reemerge, initially in Kenya, before spreading through countries in and around the Indian Ocean, resulting in millions of disease cases and the first description of severe disease and death related to this virus. Age-related clinical presentation was reported in Suriname [5].

These large-scale outbreaks eventually led to the introduction of CHIKV into more-temperate locations, with Italy reporting a local outbreak of CHIKV infection in 2007. Aggressive vector control activities combined with cooler temperatures eventually resulted in cessation of CHIKV transmission in Italy. The large-scale outbreaks also led to an increase of travel-related cases in the Americas. From 1995 to 2005, only 3 cases of chikungunya were identified in US travelers. From 2006 through 2013, 28 cases of CHIKV infection per year were reported among travelers in the United States, with most of the infections acquired in areas of Asia where there were large-scale outbreaks. Between 2013 and 2015, at least 3467 imported cases were reported in the United States [2].

CURRENT CHIKUNGUNYA SITUATION IN THE AMERICAS

The emergence (or, most likely, reemergence) of CHIKV in the Americas was announced in December 2013, when the French National Reference Center for Arboviruses diagnosed the first local chikungunya cases in Saint Martin [9–11]. At that time, this area was facing a concomitant dengue virus outbreak and the first chikungunya cases were initially identified as dengue-like fever. Chikungunya and dengue have a similar clinical presentation, which makes the clinical diagnosis difficult. Patients with either disease can present with fever, myalgia, headache, arthralgia, and rash. The different symptoms’ frequency and description of the clinical presentation may help, especially when several cases occur in identical locations and where scarce laboratory capacities limit diagnostic options [2].

Since it was first reported in Saint Martin, chikungunya has spread to 45 countries and territories in North, Central, and South America (Figure 1), causing >2.9 million suspected and confirmed cases and 296 deaths as of late July 2016 [12]. As in many other vector-borne diseases, outbreaks were mainly reported during the rainy season, when the density of mosquitoes is maximal. High disease attack rates were reported in areas such as in the Dominican Republic, (41%) or Suriname (90.4%), and the transmission peak was reached within 3 months [13, 14]. Although comparable to the attack rates noted in Malaysia (55.6%) and India (37.5%), these are higher than the attack rate observed in La Reunion (16.5%) [1, 2, 4]. Differences in attack rates are expected and may be explained by factors such as surveillance practices; season of CHIKV introduction into a country or a region, which has a direct effect on vector density and activity; vector control measures; and lifestyle differences (eg, use of air conditioning; Table 1). These factors may result in underestimation or overestimation of attack rates during an epidemic.

The illness caused by CHIKV is typically not fatal, with <1% of individuals with chikungunya in Colombia and Venezuela dying [17]. However, the real proportion of CHIKV-associated deaths is unknown and remains under investigation. The disease has also been associated with significant acute and long-term morbidity. According to a recent model based on the number of patients with acute chikungunya reported in 2014 in the Americas (n = 855 890 [12]), an estimated 385 835–429 058 persons (48%; 95% confidence interval, 45%–50%) will develop postchikungunya chronic inflammatory rheumatism in a median time of 20 months [22]. Also, the economic cost of the disease, including lost wages, in the Americas is expected to be overwhelming. A study in Venezuela has estimated the cost of chikungunya in that country to be >1 billion dollars [24].

It is currently unclear to what degree CHIKV will persist and continue to circulate in the Americas. Most of the disease that has been reported to date was likely a result of human-to-mosquito transmission. An enzootic cycle can be established among the nonhuman primates (NHPs) in Africa and the Americas, depending on a species’ susceptibility to the development of chikungunya viremia. However, no important clinical manifestations of the disease have been observed in NHPs so far, compared with yellow fever [25, 26]. Studies are necessary to assess the role of NHPs but also of other potential reservoirs (such as rodents, birds, or other vertebrates yet to be identified) in maintaining CHIKV in the environment.

CLINICAL CASE DEFINITION

Newer chikungunya case definitions were recently proposed for the Americas. The definitions include 4 categories of cases: (1) acute clinical cases, characterized by fever (temperature, >38.5°C [101.3°F]) and joint pain (usually incapacitating) with acute onset and/or epidemiological and laboratory criteria; (2) atypical cases, characterized by clinical cases of laboratory-confirmed CHIKV accompanied by other manifestations (ie, neurological, cardiovascular, dermatological, ophthalmological, hepatic, renal,
Figure 1. Areas with reported autochthonous transmission from 2013 to 2015.
respiratory, or hematological conditions); (3) severe acute cases, characterized by clinical cases of laboratory-confirmed CHIKV presenting with dysfunction of at least 1 organ or system that threatens life and requires hospitalization; and (4) suspected/confirmed chronic cases, characterized by previous clinical diagnosis of chikungunya 12 weeks after symptom onset and presentation with at least 1 rheumatologic (joint) manifestation (ie, pain, rigidity, or edema) that is continuous or recurrent [14].

**ECOLOGICAL AND ENVIRONMENTAL FACTORS**

Disease spread cannot be entirely determined by risk factors for chikungunya, but some of them may have strong influences on human (population density, activity, and migration) and vector (type, density, and infectivity) populations.

Ecological and environmental factors provide complementary information for risk assessment. Access to data and information on the environmental and demographic conditions in the area of interest, both historically and at the time of the study, may support the interpretation and analyses of CHIKV activity. The interpretation of human serosurvey findings and entomological surveillance for vector density and infectivity is enhanced with at least 1 rheumatologic (joint) manifestation (ie, pain, rigidity, or edema) that is continuous or recurrent [14].

**THE FUTURE OF CHIKUNGUNYA IN THE AMERICAS**

As of late 2015, CHIKV continues to circulate and cause disease in many of the countries in the Americas. As noted above, it is unclear whether CHIKV will establish an enzootic cycle in the Americas that would facilitate continual occurrence of CHIKV outbreaks as immunologically naive humans encroach on this cycle and become infected. If CHIKV develops an enzootic cycle like that of yellow fever virus, it may be possible for early detection to rely not only on traditional human surveillance, but also on ecologic surveillance, such as epizootic and entomological surveillance for vector density and infectivity [26]. Early risk detection using selected ecological and environmental indicators such as rain, temperature, altitude, vegetation, and land use could identify new at-risk areas where CHIKV circulation could be confirmed by local serosurveys.

The continued geographical spread of CHIKV, through travel and trade, to temperate areas with favorable virus-vector-vertebrate and environmental conditions is conceivable. Since isolated cases and outbreaks have already been reported in the United States and Europe [2, 9, 10], it is important to focus future work on identifying potential factors that might help limit the spread of CHIKV, exploring therapeutic options for both acute and chronic disease, and developing a global strategy to combat the progression of the disease.

We have gained more understanding of the epidemiology and clinical spectrum of the disease, owing to the recent outbreaks in Africa and Asia. These lessons learned will help the Americas not only to better understand the acute and chronic phases of the disease, but also to better follow up at-risk population groups.

**Notes**

*Acknowledgments.* We thank Patricia Najera from the Pan American Health Organization/World Health Organization (WHO), for designing the map of chikungunya cases reported in the Americas, and Erika Garcia, for critical reading of the manuscript.

*Disclaimer.* The authors alone are responsible for the views expressed in this publication, which do not necessarily represent the decisions, policy or views of the WHO (applies to S. Y., V. M., L. C., and P. R.-P.) or the Centers for Disease Control and Prevention (applies to J. E. S.).

*Financial support.* This work was supported by the National Institute of Allergy and Infectious Diseases and the WHO.

*Potential conflicts of interest.* All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Gerardin P, Guernier V, Perrau J, et al. Estimating chikungunya prevalence in La Reunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect Dis 2008; 8:99.
2. Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological re-
view of a re-emerging infectious disease. Clin Infect Dis 2009; 49:942–8.
3. Nakkhara P, Chongsuvivatwong V, Thammapalo S. Risk factors for symptomatic
and asymptomatic chikungunya infection. Trans R Soc Trop Med Hyg 2013;
107:789–96.
4. Ayu SM, Lai LR, Chan YF, et al. Seroprevalence survey of Chikungunya virus in
Iligan Panchor, Malaysia. Am J Trop Med Hyg 2010; 83:1245–8.
5. Genderen FT, Krishnadath I, Sno R, Grunberg MG, Zijlmans W, Adhin MR. First
chikungunya outbreak in Surinam: clinical and epidemiological features. PLoS
Negl Trop Dis 2016; 10:e0004625.
6. Gérardin P, Sampériz S, Ramful D, et al. Neurocognitive outcome of children ex-
posed to perinatal mother-to-child Chikungunya virus infection: the CHIMERE
cohort study on Reunion Island. PLoS Negl Trop Dis 2014; 8:e2996.
7. Arpino C, Curatolo P, Rezza G. Chikungunya and the nervous system: what we do
and what we do not know. Rev Med Virol 2009; 19:121–9.
8. Tsatsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chi-
kungunya virus affects vector specificity and epidemic potential. PLoS Pathog
2007; 3:e201.
9. Halstead SB. Reappearance of chikungunya, formerly called dengue, in the Amer-
cicas. Emerg Infect Dis 2015; 21:557–61.
10. Kuno G. A re-examination of the history of etiologic confusion between dengue
and chikungunya. PLoS Negl Trop Dis 2015; 9:e0004101.
11. Cassadou S, Boucau S, Petit-Sinturel M, Huc P, Leparc-Goffart I, Ledrans M.
Emergence of chikungunya fever on the French side of Saint Martin island, Octo-
ber to December 2013. Euro Surveill 2014; 19 pii:20752.
12. Pan American Health Organization. Number of reported cases of CHIK fever in
the Americas by country or territory 2013-2014, and 2015. http://www.paho.org/
hq/index.php?option=com_topics&view=readall&cid=5927&Itemid=40931&
lang=en. Accessed 2 May 2016.
13. Pimentel R, Skewes-Ramm R, Moya J. Chikungunya in the Dominican Republic:
lessons learned in the first six months (in Spanish). Rev Panam Salud Publica
2014; 36:336–41.
14. Chikungunya: case definitions for acute, atypical and chronic cases. Conclusions
of an expert consultation, Managua, Nicaragua, 20–21 May 2015. Wkly Epidemiol
Rec 2015; 90:410–4.
15. Sergen K, Yahaya AA, Brown J, et al. Seroprevalence of Chikungunya virus infec-
tion on Grande Comore Island, union of the Comoros. Am J Trop Med Hyg 2007;
76:1189–93.
16. Economopoulos A, Dominguez M, Helynck B, et al. Atypical chikungunya
virus infections: clinical manifestations, mortality and risk factors for severe dis-
ease during the 2005–2006 outbreak on Réunion. Epidemiol Infect 2009;
137:534–41.
17. Cardona-Ospina JA, Henao-SanMartin V, Paniz-Mondolí AE, Rodriguez-Morales
AJ. Mortality and fatality due to Chikungunya virus infection in Colombia. J Clin
Virol 2015; 70:14–5.
18. Feldstein LR, Ellis EM, Rowhani-Rahbar A, Halloran EM, Ellis BR. The First Re-
ported Outbreak of Chikungunya in the U.S. Virgin Islands, 2014–2015. Am J Trop
Med Hyg. 2016; pii: 16-0288.
19. Moya J, Pimentel R, Puello J. Chikungunya: un reto para los servicios de salud de la
República Dominicana. Rev Panam Salud Publica 2014; 36:331–5.
20. Powers AM, Logue CH. Changing patterns of chikungunya virus: re-emergence of
a zoonotic arbovirus. Journal of General Virology 2007; 88:2363–77.
21. Simon F, Javelle E, Cabie A, et al. Société de pathologie infectieuse de langue fran-
çaise. French guidelines for the management of chikungunya (acute and persistent
presentations). November 2014. Med Mal Infect 2015; 45:243–63.
22. Rodriguez-Morales AJ, Cardona-Ospina JA, Villamí-Gomez W, Paniz-Mondolí AE.
How many patients with post-chikungunya chronic inflammatory rheumatism can
we expect in the new endemic areas of Latin America? Rheumatol Int 2015;
35:2091–4.
23. Gérardin P, Barau G, Michauti A, et al. Multidisciplinary prospective study of
mother-to-child chikungunya virus infections on the island of La Réunion.
PLoS Med 2008; 5:e60.
24. Méndez JC, Abadi A. How much does the Chikungunya epidemic cost in Vene-
zuela [in Spanish]? http://prodavinci.com/blogs/quiere-saber-cuanto-costo-
la-epidermia-de-chikungunya-en-venezuela-por-julio-castro-y-anabella-abadi/.
Accessed 2 May 2016.
25. Inoue S, Morita K, Matias RR, et al. Distribution of three arbovirus antibodies
among monkeys (Macaca fascicularis) in the Philippines. J Med Primatol 2003;
32:89–94.
26. Almeida MA, Cardoso Jda C, Dos Santos E, et al. Surveillance for yellow Fever
virus in non-human primates in southern Brazil, 2001–2011: a tool for prioritizing
human populations for vaccination. PLoS Negl Trop Dis 2014; 8:e2741.
27. World Health Organization (WHO). Risk assessment on yellow fever virus circu-
lation in endemic countries. Working document from an informal consultation of
experts. A protocol for risk assessment at the field level. Geneva, Switzerland:
WHO, 2014.